NASDAQ:TCBPW TC Biopharm (TCBPW) Stock Price, News & Analysis → Beta testers blew this thing up (From Prosper Trading Academy) (Ad) Free TCBPW Stock Alerts $0.0097 0.00 (0.00%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$0.0065▼$0.009750-Day Range$0.01▼$0.0352-Week Range$0.00▼$0.07Volume28,113 shsAverage Volume36,897 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesShort InterestTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesShort InterestTrends Get TC Biopharm alerts: Email Address Ad Prosper Trading Academywhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's always a catch in life. You NEED to use a specific system when you trade them.Click here to download my options trading cheat sheet (5-7 stocks inside here) About TC Biopharm Stock (NASDAQ:TCBPW)TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.Read More TCBPW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCBPW Stock News HeadlinesMay 7, 2024 | benzinga.comLatest News for TC BioPharm (Holdings) Stock (NASDAQ:TCBP)January 4, 2024 | msn.comTC BioPharm regains compliance with NasdaqJanuary 3, 2024 | marketwatch.comTC BioPharm Shares Drop After Half of Workforce Gets CutJanuary 3, 2024 | finance.yahoo.comTC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline EfficienciesDecember 19, 2023 | marketwatch.comTC BioPharm Shares Tumble After Offering Gets PricedDecember 13, 2023 | msn.comTC Biopharm plans to implement ADS ratio changeDecember 13, 2023 | finance.yahoo.comTC BioPharm Announces Plan to Implement ADS Ratio ChangeNovember 28, 2023 | msn.comTC BioPharm receives FDA approval for AML cell therapy trialNovember 2, 2023 | marketwatch.comTC BioPharm Inks Trial-Management Deal With Fortrea Amid Cost CuttingNovember 2, 2023 | finance.yahoo.comTC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical TrialsOctober 30, 2023 | morningstar.comADRs End Higher; TC Biopharm PLC Climbs 19%October 25, 2023 | finance.yahoo.comTC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial RequirementsOctober 23, 2023 | markets.businessinsider.comTC BioPharm Announces Filing Of IND For TCB-008 - Quick FactsOctober 23, 2023 | finance.yahoo.comTC BioPharm Announces Submission of Investigational New Drug (IND) Application to U.S. FDA for Treatment of Relapse/Refractory AMLOctober 12, 2023 | finance.yahoo.comTC Biopharm (Holdings) Plc (TCBPW)September 27, 2023 | finance.yahoo.comTC BioPharm to Present at the LD Micro Main Event XVIJuly 31, 2023 | finance.yahoo.comTC BioPharm Maintains Nasdaq ListingJuly 6, 2023 | finance.yahoo.comTC BioPharm CEO, Bryan Kobel, is Featured on The Stock Day PodcastMay 24, 2023 | finance.yahoo.comTC BioPharm to Present at LD Micro Invitational XIII Conference on June 7, 2023March 30, 2023 | finance.yahoo.comTC BioPharm Announces Closing of $5.5 Million Public OfferingMarch 28, 2023 | morningstar.comADRs End Higher, Ambev and TC BioPharm Trade HigherMarch 28, 2023 | finance.yahoo.comTC BioPharm Announces Pricing of $5.5 Million Public OfferingMarch 22, 2023 | markets.businessinsider.comTC BioPharm Unveils Corporate Restructuring Plan; To Cut Up To 30% Of WorkforceMarch 22, 2023 | finance.yahoo.comTC Biopharm Announces Corporate Restructuring, Reduction in OverheadMarch 7, 2023 | finance.yahoo.comTC BioPharm Shifts Focus to FDA Clinical TrialsSee More Headlines Receive TCBPW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TC Biopharm and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:TCBPW CUSIPN/A CIK1872812 Webwww.tcbiopharm.com Phone44 14 1433 7557FaxN/AEmployees41Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.86 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Bryan L. Kobel (Age 45)CEO & Director Mr. Martin E. Thorp (Age 72)CFO & Director Mr. Christopher CamarraExecutive Vice President of CommunicationsDr. Lauren Bor Ph.D.Head of Commercial Development DivisionKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors TCBPW Stock Analysis - Frequently Asked Questions How have TCBPW shares performed in 2024? TC Biopharm's stock was trading at $0.0325 on January 1st, 2024. Since then, TCBPW stock has decreased by 70.2% and is now trading at $0.0097. View the best growth stocks for 2024 here. How do I buy shares of TC Biopharm? Shares of TCBPW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TCBPW) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TC Biopharm (Holdings) Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share TC Biopharm With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.